Compare Recursion Pharmaceuticals Inc (RXRX) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Trip.com Group Ltd — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.86B), while Trip.com Group Ltd trades at $39.23 (market cap $26.04B). The key difference: Trip.com Group Ltd is far larger — about 14× Recursion Pharmaceuticals Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | TCOM | |
|---|---|---|
Market Cap | $1.86B | $26.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $78.96 |
52-Week Low | $2.84 | $39.19 |
Enterprise Value | $1.38B | $18.64B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Trip.com (TCOM) trades at $40.50, down 1.29% with bearish technical signals despite strong fundamentals. The company reported robust 2025 results with $62.41B revenue and 53.34% net margin, though recent quarters show earnings misses. Valuation metrics appear attractive with P/E of 6.01 and EV/EBITDA of 3.21. However, the stock faces headwinds from a recent $770M Chinese antitrust penalty and declining cash flow trends.
The investment case balances deep value against regulatory risks. Analyst consensus remains bullish with $59.29 price target (47% upside), but technical weakness and China regulatory overhang create near-term uncertainty. Long-term growth prospects in travel recovery support the bull case, though investors should monitor Q2 2026 earnings due September 15 for confirmation of business momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
